Aktis Oncology, Inc.
AKTS
$20.34
$1.226.38%
NASDAQ
| 03/31/2026 | 12/31/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | 3.23M | 1.87M | 1.45M | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 3.23M | 1.87M | 1.45M | ||
| Cost of Revenue | 20.04M | 16.49M | 15.86M | ||
| Gross Profit | -16.81M | -14.62M | -14.42M | ||
| SG&A Expenses | 5.90M | 2.75M | 3.73M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 25.93M | 19.25M | 19.59M | ||
| Operating Income | -22.71M | -17.38M | -18.14M | ||
| Income Before Tax | -18.33M | -15.14M | -14.99M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -18.33M | -15.14M | -14.99M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -18.33M | -15.14M | -14.99M | ||
| EBIT | -22.71M | -17.38M | -18.14M | ||
| EBITDA | -22.05M | -16.68M | -17.66M | ||
| EPS Basic | -0.38 | -18.21 | -18.60 | ||
| Normalized Basic EPS | -0.24 | -11.38 | -11.62 | ||
| EPS Diluted | -0.38 | -18.21 | -18.60 | ||
| Normalized Diluted EPS | -0.24 | -11.38 | -11.62 | ||
| Average Basic Shares Outstanding | 48.63M | 831.20K | 805.80K | ||
| Average Diluted Shares Outstanding | 48.63M | 831.20K | 805.80K | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||